Clinical utility of anti-MOG antibody testing in a Danish cohort
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Clinical utility of anti-MOG antibody testing in a Danish cohort. / Papp, Viktoria; Langkilde, Annika R; Blinkenberg, Morten; Schreiber, Karen; Jensen, Poul Erik Hyldgaard; Sellebjerg, Finn.
In: Multiple Sclerosis and Related Disorders, Vol. 26, 2018, p. 61-67.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Clinical utility of anti-MOG antibody testing in a Danish cohort
AU - Papp, Viktoria
AU - Langkilde, Annika R
AU - Blinkenberg, Morten
AU - Schreiber, Karen
AU - Jensen, Poul Erik Hyldgaard
AU - Sellebjerg, Finn
N1 - Copyright © 2018 Elsevier B.V. All rights reserved.
PY - 2018
Y1 - 2018
N2 - BACKGROUND: Anti-myelin oligodendrocyte glycoprotein (MOG) antibody (Ab) can be found in different immune-mediated inflammatory CNS disorders. The full range of clinical manifestations may not have been fully discovered yet.METHODS: In a cross-sectional study 184 adults (age ≥ 16) were tested for anti-MOG antibody (Ab) with a cell-based assay. To define the relevant target population for anti-MOG antibody testing in a neurology clinic, we divided the entire study population based on the presenting symptoms and classified cases followed for multiple sclerosis (MS) according to the clinical features and response to disease-modifying therapy.RESULTS: We identified eight (4.4%) MOG-Ab positive cases in the whole cohort. All eight cases had first manifestations suggestive of neuromyelitis optica spectrum disorder (NMOSD), but had highly variable disease courses and responses to therapy. This included a patient with chronic relapsing inflammatory optic neuropathy (CRION) responding only to therapy with infliximab. Four (3%) out of 134 cases followed for MS who tested positive for anti-MOG Ab showed atypical features and had poor response to therapy.CONCLUSION: A broad range of clinical and radiological features of anti-MOG associated disorder was observed in a single centre. MOG-Ab testing should be considered in patients with an NMOSD phenotype and in MS patients presenting atypical features. The potential use of infliximab therapy for MOG-Ab disease should be further investigated.
AB - BACKGROUND: Anti-myelin oligodendrocyte glycoprotein (MOG) antibody (Ab) can be found in different immune-mediated inflammatory CNS disorders. The full range of clinical manifestations may not have been fully discovered yet.METHODS: In a cross-sectional study 184 adults (age ≥ 16) were tested for anti-MOG antibody (Ab) with a cell-based assay. To define the relevant target population for anti-MOG antibody testing in a neurology clinic, we divided the entire study population based on the presenting symptoms and classified cases followed for multiple sclerosis (MS) according to the clinical features and response to disease-modifying therapy.RESULTS: We identified eight (4.4%) MOG-Ab positive cases in the whole cohort. All eight cases had first manifestations suggestive of neuromyelitis optica spectrum disorder (NMOSD), but had highly variable disease courses and responses to therapy. This included a patient with chronic relapsing inflammatory optic neuropathy (CRION) responding only to therapy with infliximab. Four (3%) out of 134 cases followed for MS who tested positive for anti-MOG Ab showed atypical features and had poor response to therapy.CONCLUSION: A broad range of clinical and radiological features of anti-MOG associated disorder was observed in a single centre. MOG-Ab testing should be considered in patients with an NMOSD phenotype and in MS patients presenting atypical features. The potential use of infliximab therapy for MOG-Ab disease should be further investigated.
KW - Adolescent
KW - Adult
KW - Anti-Inflammatory Agents/pharmacology
KW - Autoantibodies/blood
KW - Cross-Sectional Studies
KW - Denmark
KW - Female
KW - Humans
KW - Infliximab/pharmacology
KW - Male
KW - Middle Aged
KW - Multiple Sclerosis/blood
KW - Myelin-Oligodendrocyte Glycoprotein/immunology
KW - Neuromyelitis Optica/blood
KW - Optic Neuritis/blood
KW - Young Adult
U2 - 10.1016/j.msard.2018.09.010
DO - 10.1016/j.msard.2018.09.010
M3 - Journal article
C2 - 30227311
VL - 26
SP - 61
EP - 67
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
SN - 2211-0348
ER -
ID: 216466726